Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down – Should You Sell?

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) gapped down prior to trading on Wednesday . The stock had previously closed at $45.98, but opened at $44.75. Kymera Therapeutics shares last traded at $44.75, with a volume of 4,250 shares trading hands.

Analyst Ratings Changes

KYMR has been the topic of a number of research analyst reports. Stephens initiated coverage on Kymera Therapeutics in a report on Monday, November 18th. They set an “overweight” rating and a $65.00 price target on the stock. Truist Financial reaffirmed a “buy” rating and set a $53.00 target price (down from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th. UBS Group lowered their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Finally, Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, August 26th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $52.13.

Kymera Therapeutics Stock Performance

The stock has a 50-day simple moving average of $46.91 and a 200 day simple moving average of $42.04.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm’s revenue was down 20.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.90) EPS. Equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Values First Advisors Inc. bought a new position in Kymera Therapeutics in the 3rd quarter worth approximately $61,000. Quarry LP bought a new position in Kymera Therapeutics in the 3rd quarter worth approximately $95,000. Mirae Asset Global Investments Co. Ltd. increased its position in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after buying an additional 504 shares during the period. Comerica Bank increased its position in Kymera Therapeutics by 13.7% in the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after buying an additional 400 shares during the period. Finally, Public Employees Retirement Association of Colorado bought a new position in Kymera Therapeutics in the 2nd quarter worth approximately $139,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.